TheraRadar
Clinical-Stage Companies / PT. Prodia Stem Cell Indonesia

PT. Prodia Stem Cell Indonesia

Pre-Approval PRO BETA
12
Total Trials
1
Phase 3
12
Phase 2
6
Recruiting
159
Score

Pipeline by Phase

Phase 3
1
Phase 2
12
Phase 1
11

Therapeutic Focus

Retinitis Pigmentosa Acute Respiratory Distress Syndrome Ischemic Stroke Nasopharyngeal Cancer Liver Cirrhoses

Clinical Trials (12)

NCT05909488 Phase 2 NOT YET RECRUITING

Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

Started: 5/1/2026

NCT07439848 Phase 1 RECRUITING

Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis

Started: 12/25/2023

NCT07429253 Phase 1 RECRUITING

Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients

Started: 1/9/2026

NCT07396155 Phase 1 RECRUITING

Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial

Started: 7/1/2026

NCT05008588 Phase 1 ACTIVE NOT RECRUITING

Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct

Started: 5/30/2022

NCT05261750 Phase 1 ACTIVE NOT RECRUITING

Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer

Started: 4/30/2022

NCT04357600 Phase 1 ENROLLING BY INVITATION

Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B

Started: 5/17/2018

NCT05279768 Phase 1 COMPLETED

Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance.

Started: 9/1/2022

NCT04314687 Phase 1 ACTIVE NOT RECRUITING

Stem Cell and Conditioned Medium for Cerebral Palsy

Started: 10/13/2021

NCT04314661 Phase 1 COMPLETED

Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis

Started: 8/3/2020

NCT04340609 Phase 1 COMPLETED

Stem Cell in Acute Myocardial Infarction

Started: 3/11/2019

NCT04315025 Phase 1 COMPLETED

Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa

Started: 10/7/2018

Drug Candidates

UC-MSC UC-MSC and Secretome Conditioned Medium Umbilical Cord Mesenchymal Stem Cells Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy) Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy) Allogeneic Umbilical Cord Mesenchymal Stem Cell UC-MSCs Secretomes UC-MSCs and Secretomes
Activity Status: Active
Last Trial Started: 7/1/2026
Last Trial Ended: 1/20/2025
Trials (12 months): 3
Completed Trials: 4
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.